Advanced

Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor

Turpie, Alexander G. G.; Kreutz, Reinhold; Llau, Juan; Norrving, Bo LU and Haas, Sylvia (2012) In Thrombosis and Haemostasis 108(5). p.876-886
Abstract
A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have shown considerable promise in large-scale, randomised clinical studies for the management of thromboembolic disorders, and have been approved for clinical use in specific indications. Rivaroxaban is licensed for the prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery, the treatment of deep-vein thrombosis and prevention of recurrent venous thromboembolism, and for stroke prevention in patients with non-valvular atrial fibrillation. Based on the clinical trial... (More)
A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have shown considerable promise in large-scale, randomised clinical studies for the management of thromboembolic disorders, and have been approved for clinical use in specific indications. Rivaroxaban is licensed for the prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery, the treatment of deep-vein thrombosis and prevention of recurrent venous thromboembolism, and for stroke prevention in patients with non-valvular atrial fibrillation. Based on the clinical trial data for rivaroxaban, feedback on its use in clinical practice and the authors' experience with the use of rivaroxaban, practical guidance for the use of rivaroxaban in special patient populations and specific clinical situations is provided. Although most recommendations are in line with the European summary of product characteristics for the approved indications, additional and, in several areas, different recommendations are given based on review of the literature and the authors' clinical experience. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Anticoagulant, practical management, recommendations, rivaroxaban
in
Thrombosis and Haemostasis
volume
108
issue
5
pages
876 - 886
publisher
F K Schattauer Verlag Gmbh
external identifiers
  • wos:000311259600011
  • scopus:84870032549
ISSN
0340-6245
DOI
10.1160/TH12-03-0209
language
English
LU publication?
yes
id
675cb3a7-7488-46b5-b8d7-8c3b456da69b (old id 3388460)
date added to LUP
2013-02-01 07:04:06
date last changed
2017-10-22 04:23:14
@article{675cb3a7-7488-46b5-b8d7-8c3b456da69b,
  abstract     = {A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have shown considerable promise in large-scale, randomised clinical studies for the management of thromboembolic disorders, and have been approved for clinical use in specific indications. Rivaroxaban is licensed for the prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery, the treatment of deep-vein thrombosis and prevention of recurrent venous thromboembolism, and for stroke prevention in patients with non-valvular atrial fibrillation. Based on the clinical trial data for rivaroxaban, feedback on its use in clinical practice and the authors' experience with the use of rivaroxaban, practical guidance for the use of rivaroxaban in special patient populations and specific clinical situations is provided. Although most recommendations are in line with the European summary of product characteristics for the approved indications, additional and, in several areas, different recommendations are given based on review of the literature and the authors' clinical experience.},
  author       = {Turpie, Alexander G. G. and Kreutz, Reinhold and Llau, Juan and Norrving, Bo and Haas, Sylvia},
  issn         = {0340-6245},
  keyword      = {Anticoagulant,practical management,recommendations,rivaroxaban},
  language     = {eng},
  number       = {5},
  pages        = {876--886},
  publisher    = {F K Schattauer Verlag Gmbh},
  series       = {Thrombosis and Haemostasis},
  title        = {Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor},
  url          = {http://dx.doi.org/10.1160/TH12-03-0209},
  volume       = {108},
  year         = {2012},
}